S2 Part 1: Processing and minor processing

Published Date: 16 Feb 2023

Dr. Jacob Sands and Dr. Jared Weiss talk about subtypes. ongoing clinical trials; sustained sustained response to treatment; And it is possible to use the word "cure" to treat a small breast cancer.

Read Full News

Latest News

HF With Improved Ejection Fraction

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

S2 Episode 6: A Futuristic Vision for Treating Myelofibrosis

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Radiofrequency Ablation: A First-Line Treatment Option

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

S2 Episode 5: DNA Repair and Replication Stress in Endometrial Cancer

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

May 09 2025 This Week in Cardiology

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

Should All Newborns Be Screened for Congenital Hypothyroidism?

Drs Kaniksha Desai and Larry Fox discuss congenital hypothyroidism, including when to test and how to treat it.

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Latest News

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

Drs Kaniksha Desai and Larry Fox discuss congenital hypothyroidism, including when to test and how to treat it.

News All Time

S2 Episode 2: Endometrial Cancer Disparities: Access to Care and Trials

Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

S2 Episode 1: Hormonal Therapy Updates in Metastatic Endometrial Cancer

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer.

Managing Familial Hypercholesterolemia in Primary Care

Familial hypercholesterolemia is often diagnosed late, and patients with the condition are significantly undertreated.

IgA Nephropathy: 5 Differential Diagnoses to Know

IgAN diagnosis is complex, and differentiation from other glomerulopathies is critical. Consider these five important differentials to ensure timely diagnosis and appropriate treatment.

Q&A: Are You Sure the Diagnosis Is IgA Nephropathy?

Arnold B. Alper, MD, discusses the IgA nephropathy differential diagnosis.

SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer

Dr Avan Armaghani discusses the clinical impact of several studies presented at SABCS.

Key Updates in Early Breast Cancer From SABCS 2024

Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

More Than Hives: Discussing Chronic Spontaneous Urticaria

Dermatologists discuss common roadblocks in communicating with patients with chronic spontaneous urticaria, who often search for a cause they can fix for a condition lacking in community resources.

Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes?

A commentary on the need for better trials and long-term data for the myosin inhibitors aficamten and mavacamten in obstructive hypertrophic cardiomyopathy.

New Directions in Anemia and Related Disorders From ASH 2024

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Episode 6: HER2-Ultra-Low Breast Cancer

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

Growth Hormone and the Thyroid Gland: A Complex Relationship

Drs Kaniksha Desai and Laurence Katznelson discuss the complex relationship between growth hormone and the thyroid gland.

ACR 2024: Key Insights on Updated Lupus Nephritis Guidelines

Dr Bella Mehta reviews new guidance on frequent monitoring, triple therapy, early biopsy, and reduced steroids for better outcomes.

Episode 5: Sequencing of ADCs for Metastatic HER2-Low Disease

Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.

Glomerular Disease Highlights From ASN Kidney Week 2024

Glomerular disease highlights from ASN 2024 include data on atacicept benefits in IgA nephropathy, protein reduction from pegcetacoplan, and a possible new therapy for membranous nephropathy.

Thrombocytosis and Cancer Risk: Management in Primary Care

Dr Kevin Fernando discusses managing thrombocytosis and the risk for cancer in primary care.

Recommended News For You

In a study, immune detection of oral cancers is linked to obesity.

Fear of hair loss might cause some to reject cancer treatment

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

Many Americans unaware of links between HPV and cancers, poll reveals

Gene therapy for glioblastoma is effectively created by researchers.

Liver cancer cells under pressure: Compression can spark invasion, drug resistance and altered gene activity

Recommended Articles For You

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More 

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer 

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection 

Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prostate cancer early detection system eliminates need for biopsy.

2.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

3.

3D virtual staining technology enables non-invasive observation of cancer tissue

4.

Healthcare in the Mix in President Biden's Farewell Address

5.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

1.

Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms 

2.

Uncovering the Causes of Thrombocytosis: A Journey to Improved Health

3.

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis

4.

Multiple Myeloma: Understanding the Basics 

5.

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

3.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot